Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Director Shareholding

24 Feb 2005 07:04

Marchpole Holdings PLC24 February 2005 24 February 2005 Marchpole Holdings plc (the 'Company') Directors' interests Following approval by the Remuneration Committee, the executive Directors of theCompany have been granted the following share options ('Options') over newordinary shares of 1 pence each ('Ordinary Shares') under the Marchpole Holdingsplc 2002 Unapproved Share Option Scheme adopted by the Company at the AnnualGeneral Meeting held on 31 October 2002. All Options were granted on 21 February 2005, are exercisable at a price of25.75 pence per share and vest and become exercisable in three equal tranches onand from each twelfth month anniversary of the date of grant on the attainmentof a market capitalisation of the Company of £60 million, £70 million and £80million respectively. Director Number of Options over new Ordinary SharesGreg Tufnell, Chief Executive 900,000Justin Hampshire, Finance Director 900,000Michael Morris, Executive Director 900,000 The additional grant of 3,250,000 Options in the Company has been made toMichael Morris at a exercise price of 25.75 pence per share, such share optionsvesting and becoming exercisable in two equal tranches on each twelfth monthanniversary on the date of grant and on the achievement of a marketcapitalisation of the Company of £50 million and £55 million respectively. The Directors have the following interests in the Company: Director Number of Ordinary % of issued Shares share capital Christopher Phillips, Chairman 500,000 0.38Greg Tufnell, Chief Executive - -Justin Hampshire, Finance Director 500,000 0.38Michael Morris, Executive Director 25,521,715 19.21Raymond Harris, Non-Executive Director 30,000 0.02 The Michael Morris 1997 Trust 10,000,000 7.55 Enquiries: Justin Hampshire, Marchpole Holdings 020 7908 7777 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.